Tuesday, August 23, 2005

AMLN Stock Takes Off (Again)

Amylin Pharmaceuticals announced that that results from an ongoing mid-stage study showed that a long-acting form of their Byetta injection helped patients with type 2 diabetes improve glucose control.

At the time of publication, AMLN was up another $5 after a collosal day on Monday.

The stock was also mentioned on Monday's Mad Money, as well.

Clearly, Cramer moves markets.

As does Barrons, which had a great feature on diabetes 2 weeks ago.

Diabetes affects an estimated 194 million adults worldwide and more than 18 million in the U.S. About 90 percent to 95 percent of those affected have type 2 diabetes, a condition where the body does not produce enough insulin.

Diabetes is the fifth leading cause of death by disease in the United States.

As we said yesterday, the bottom line is this: As Big Pharma battles with litigation and the onslaught of generic drugs, the best bet for investors in the industry remains with these small biotech companies burning through cash but also creating some of the most marvellous drugs of our time.

Subsequently, that makes them acquisition targets, which you got to love.

About Us | In the News | Management | Contact Us | Archive | Premium Membership | Terms of Use | Privacy Policy | Careers | FAQ

All quotes are 15 minutes delayed. Copyright © 2006 by Catablast! Media Group LLC, part of the SeekingAlpha network. Web Design by Synexio Systems. All Rights Reserved.